Harrow, Inc. HROW R2K
Company Overview
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Why Investors Should Care
Revenue has grown at a 134.2% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $272.30M (+36.4% YoY); net profit $-5.14M.
- Trailing 12 Months Year-on-year growth — revenue -7.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 134.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 134.20% |
| 1 Year: | -7.60% |
Stock Price Performance
| 1 Year: | +16.14% |
| 6 Months: | -11.56% |
| 3 Months: | +11.51% |
| 1 Month: | +9.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.71 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 134.2% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | HROW Harrow, Inc. R2K | 41.37 | -108.87 | $1.54B | 0.00% | 10.06% | -35.43% | 134.20% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.48M | 8.87M | 10.38M | 10.74M | 12.29M | 13.52M | 12.76M | 11.82M | 8.06M | 14.40M | 15.44M | 18.13M | 18.71M | 22.12M | 23.32M | 22.82M | 26.10M | 33.47M | 34.27M | 34.59M | 48.94M | 49.26M | 47.83M | 63.74M | 71.64M | 44.20M |
| Gross Profit | - | 2.50K | 2.50K | 2.00K | 191.00K | 202.00K | 556.00K | 917.00K | 1.48M | 2.13M | 2.73M | 2.52M | 2.74M | 3.57M | 3.08M | 4.79M | 6.23M | 6.55M | 8.39M | 8.29M | 8.69M | 8.19M | 4.86M | 10.70M | 11.67M | 13.72M | 13.76M | 16.16M | 16.79M | 16.10M | 17.83M | 23.47M | 24.20M | 24.03M | 36.40M | 37.24M | 32.31M | 47.51M | 53.93M | 27.05M |
| Operating Income | -1.47M | -2.23M | -2.09M | -2.33M | -2.60M | -2.46M | -3.12M | -3.48M | -3.53M | -3.75M | -4.01M | -4.61M | -4.23M | -3.02M | -2.76M | -1.78M | -624.00K | -649.00K | -556.00K | -767.00K | -4.40M | -628.00K | -3.21M | 1.60M | 2.92M | 4.17M | -3.72M | 2.10M | 1.69M | -94.00K | 1.21M | 2.35M | 1.74M | -6.93M | 1.53M | 1.32M | -11.23M | 11.41M | 14.75M | -22.08M |
| Net Income | -1.47M | -2.22M | -2.08M | -2.33M | -2.60M | -2.45M | -3.09M | -3.73M | -3.95M | -4.50M | -4.64M | -3.85M | -5.01M | 1.48M | -5.69M | -3.51M | 2.52M | -2.51M | 11.36M | -2.38M | -11.47M | -12.91M | -237.00K | 8.64M | 217.00K | -2.48M | -8.33M | -2.44M | -6.24M | -6.46M | -6.64M | -4.23M | -4.39M | -13.56M | -6.47M | -4.22M | -17.78M | 5.00M | 1.02M | -27.60M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.35 | - | - | 0.06 | - | -0.17 | 0.11 | - | 0.43 | -0.09 | -0.45 | -0.50 | -0.01 | 0.32 | 0.01 | - | -0.31 | -0.09 | -0.23 | -0.24 | -0.22 | -0.14 | -0.13 | -0.38 | -0.18 | -0.12 | -0.50 | 0.13 | 0.03 | -0.74 |
| R&D Expense | 455.10K | 677.35K | 469.48K | 60.00K | 36.00K | 70.00K | 181.00K | 25.00K | 93.00K | 46.00K | 76.00K | 16.00K | 160.00K | 101.00K | 63.00K | 87.00K | 72.00K | 233.00K | 405.00K | 810.00K | 444.00K | 403.00K | 749.00K | 670.00K | 592.00K | 425.00K | 6.12M | 658.00K | 914.00K | 775.00K | 734.00K | 1.16M | 1.42M | 2.15M | 3.05M | 2.27M | 3.03M | 2.87M | 3.32M | 5.89M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.00K | 1.66M | 9.72M | 19.94M | 26.77M | 41.37M | 51.16M | 48.87M | 72.48M | 88.59M | 130.19M | 199.61M | 272.30M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.00K | 567.00K | 4.51M | 10.11M | 13.27M | 24.85M | 34.42M | 34.41M | 54.26M | 63.21M | 90.55M | 150.37M | 204.37M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | - | -2.50M | -939.23K | -4.18M | -7.69M | -10.15M | -14.82M | -15.88M | -12.16M | -5.22M | -4.79M | 385.00K | 1.61M | 1.92M | 431.00K | 8.82M | 30.52M |
| Net Income | -204.00K | -213.09K | -208.42K | -228.22K | -207.20K | -508.23K | -539.62K | -584.23K | -4.28M | -3.30M | -4.55M | -2.53M | -953.94K | -5.38M | -7.64M | -10.12M | -15.90M | -19.09M | -11.98M | 14.62M | 168.00K | -3.36M | -18.01M | -14.09M | -24.41M | -17.48M | -5.14M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.60 | 0.61 | 0.01 | -0.13 | - | -0.51 | -0.75 | -0.49 | -0.14 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | - | 194.59K | 111.55K | 1.30M | 1.62M | 237.00K | 332.00K | 739.00K | 413.00K | 825.00K | 2.08M | 2.41M | 11.08M | 3.05M | 6.65M | 12.23M | 20.94M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 1998 | Dec 1998 | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 352.29K | 160.96K | 10.71M | 15.76M | 10.24M | 14.13M | 27.25M | 23.92M | 49.45M | 59.09M | 57.47M | 98.33M | 157.38M | 312.16M | 388.97M | 399.48M |
| Total Equity | 0 | 0 | -4.00K | -11.09K | -19.51K | -47.73K | -54.92K | -163.15K | -272.77K | -406.00K | 3.49M | 4.57M | 577.21K | -1.04M | -1.70M | 10.00M | 15.11M | 8.15M | -1.39M | 6.43M | 2.62M | 24.75M | 27.71M | 27.18M | 11.29M | 27.59M | 70.77M | 69.65M | 52.45M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | - | - | 1.59M | 291.46K | 146.16K | 10.04M | 15.58M | 8.21M | 2.69M | 8.85M | 4.02M | - | 4.75M | 4.10M | 42.17M | 96.27M | 74.08M | 47.25M | 72.93M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.46M | 23.46M | - | 20.00M | 103.03M | 151.77M | 246.72M | 262.74M | 250.00M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.39M | 1.86M | - | 650.63K | 2.09M | 15.52M | 20.82M | 21.30M | 24.70M | 31.67M | 30.65M | 87.40M | 130.14M | 241.75M | 319.67M | 347.39M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | 335.04K | 1.86M | 709.56K | 650.63K | 1.56M | 5.37M | 9.90M | 5.77M | 11.90M | 12.28M | 10.80M | 9.72M | 18.63M | 49.34M | 91.34M | 96.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.30M | -291.16K | -1.90M | -4.44M | -7.06M | -11.14M | -11.21M | -8.80M | 687.00K | 950.00K | -1.10M | 5.08M | 1.71M | 3.84M | -22.20M | 43.86M |
| Investing Cash Flow | 0 | 0 | -15.49K | -70.00K | -910.00K | -5.13M | -7.29M | -961.00K | -2.20M | -1.83M | -981.00K | -18.69M | -1.74M | -152.55M | -33.16M | -5.46M |
| Financing Cash Flow | 1.00M | 145.86K | 11.81M | 10.05M | 599.00K | 10.75M | 24.67M | 4.93M | 4.13M | -1.01M | 1.43M | 51.47M | 54.14M | 126.53M | 28.53M | -12.72M |
| Capital Expenditure | -0 | -0 | -15.49K | -20.00K | -174.00K | 995.00K | -6.89M | -772.00K | -1.77M | -1.47M | -862.00K | -1.79M | -2.60M | -1.46M | -1.59M | -887.00K |
| Free Cash Flow | -2.30M | -291.16K | -1.92M | -4.46M | -7.23M | -10.15M | -18.10M | -9.57M | -1.08M | -518.00K | -1.96M | 3.30M | -892.00K | 2.38M | -23.80M | 42.98M |
| Share Buybacks | - | - | - | 191 | -13.00K | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 100.0% | 34.2% | 46.4% | 50.7% | 49.6% | 60.1% | 67.3% | 70.4% | 74.9% | 71.3% | 69.6% | 75.3% | 75.1% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -76,868.8% | -611.3% | -152.6% | -79.6% | -45.4% | -12.6% | -9.4% | 0.8% | 2.2% | 2.2% | 0.3% | 4.4% | 11.2% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -76,431.2% | -609.5% | -163.6% | -95.7% | -44.8% | 35.3% | 0.3% | -6.9% | -24.8% | -15.9% | -18.7% | -8.8% | -1.9% |
| ROE % | 5,100.0% | 1,921.1% | 1,068.2% | 478.2% | 377.2% | 311.5% | 197.8% | 143.9% | -122.7% | -72.3% | -788.9% | 243.8% | 56.1% | -53.9% | -50.6% | -124.1% | 1,147.9% | -296.8% | -458.3% | 59.1% | 0.6% | -12.3% | -159.6% | -51.0% | -34.5% | -25.1% | -9.8% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | -14,501.7% | 55.2% | -41.8% | -50.9% | -116.9% | -169.3% | -91.6% | -67.0% | -13.9% | -10.2% | 0.8% | 1.8% | 1.4% | 0.2% | 3.0% | 10.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 7.60% | 2.83M | $122.51M |
| 2 | Blackrock Inc. | 6.85% | 2.55M | $110.42M |
| 3 | Private Capital Management, LLC | 4.19% | 1.56M | $67.56M |
| 4 | Vanguard Capital Management LLC | 3.76% | 1.40M | $60.69M |
| 5 | Luxor Capital Group, LP | 3.00% | 1.12M | $48.42M |
| 6 | State Street Corporation | 2.29% | 855.05K | $36.99M |
| 7 | Geode Capital Management, LLC | 2.29% | 852.03K | $36.85M |
| 8 | Marshall Wace LLP | 1.73% | 644.92K | $27.90M |
| 9 | Dimensional Fund Advisors LP | 1.55% | 579.52K | $25.07M |
| 10 | Ikarian Capital, LLC | 1.46% | 543.05K | $23.49M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for HROW
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOQy1DWHFQcFBfVWtxUHN3SG5sMFdQLVR2SGxFUjNwNFdYLWZRdk9FZVhfX3FWd0J0YlBkUGozLWgzTUczREhJNXZZc1VST3J4RS1MNkJQMk1ScWVrWHdfblFSRkExMGU5YzhfMy1LU0VVaDBHQXZMSU50WldHRXNsT0ZyZHZGdFpHVV9YVV…
Harrow brings an interchangeable eye-drug biosimilar to U.S. retina care - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNcGRGQnBLTl90ZUI5QmJENkZTR2xrN1RDUjF5Z3d4WDNQQW93dUM0eS1UcGJjbDg5dHFON1U3emNvTTIxZHYyV2ZMbFlnY0dSZEJjV2k5SXdvNExneXNzdVZtQUdyX0sxYzNER1lzbTJqOFBndVo0SXB6SWJLYUhneE85amNzOVY3cWtoYX…
How Investors May Respond To Harrow (HROW) Taking Over BYOOVIZ US Commercialization And Ophthalmic Biosimilars - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNeFhCYlhyalcwc1F2Yjl2SjdxdkhleXVxZlZoVFU4NnVPUnc0SlZmWVVSY1hzWV82eHNPZFFzVndjOXQzMTZDekloU3FQNTRyMTBZRWZCSjVwaGtrSDNrSi10U2JLSTEtVEkwNm1hczl0dmMySVFNWmZLV214VmZpN2FKNHc4MEVRVE5PMD…
Harrow Inc. (HROW) stock falls on Q1 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxOMXVqVWc1eHlqejRrNDJ3c2cwZ1ZNQXNKVUZhanp3SEtDM3FGQVhIdF93WVBzTF9ZZVh0b2RlaGlHNWNxSUNkZkNFbGJsVjEtUWJvd2cyYTdpQ3E5QmxTZGt5QVJfWWZhbDlNZTlRd1NadllyZmpLTUIxWjRJc0wtazZ2aENoTFFUTzRfRG…
Harrow: Now Is The Buy Time (NASDAQ:HROW) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE5NbHdyQkVsWG03ekRCSHlCTnBmWGc3eW95QkIyd3VmdGhQa196ZTR0bXNPcXlLV0RPb2dvQ0Y0WXhSN3o5RDUzNmxtSW1mTEVrRlRpUldsbF9QakdfT1dvYmNPMEI5aFVmQVR2TTZYcERtWFFJRVdoVE9zLU9sdw?oc=5" target="_blan…
HROW Stock Rips Higher As Traders Digest Mixed Quarter - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5rb01ieVN2a1NsR3htbThiNzNrX0lnbWpON1FxWThTNGg1TWV5bjVWeXRiX1FKTFF0UjdDYUdyR09VVmlJMlVaNE5YUHpOMFBqMG5KcmpOdS1WdHlXdXdRVGhraHFhQ1JUeXFIUmEyOHVuU2dpMjRtclln?oc=5" target="_blank">HRO…
HROW — Frequently Asked Questions
What is the current share price of Harrow, Inc. (HROW)?
As of 2026-07-14 21:23 PDT, Harrow, Inc. (HROW) trades at $41.37 on NasdaqGM. Its 52-week range is $29.03 to $54.80.
What is the market capitalisation of HROW?
Harrow, Inc. (HROW) has a market capitalisation of $1.54B on NasdaqGM.
What is the P/E ratio of HROW?
HROW trades at a trailing price-to-earnings (P/E) ratio of -108.87. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 48.88.
What is the return on equity (ROE) of HROW?
HROW has a return on equity (ROE) of -35.43%. Its return on capital employed (ROCE) is 10.06%.
Is HROW a good stock to buy?
This page provides a data-driven analysis of Harrow, Inc. (HROW), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.